Arbour, Kathryn C.

Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing

Rizvi, H., Sanchez-Vega, F., La, K., Chatila, W., Jonsson, P., Halpenny, D., Plodkowski, A., Long, N., Sauter, J. L., Rekhtman, N., et al. (2018) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 1,367

Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer.

Arbour, K. C., Mezquita, L., Long, N., Rizvi, H., Auclin, E., Ni, A., Martínez-Bernal, G., Ferrara, R., Lai, W. V., Hendriks, L. E. L., et al. (2018) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment

Cited by 1,071

Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer

Derosa, L., Hellmann, M. D., Spaziano, M., Halpenny, D., Fidelle, M., Rizvi, H., Long, N., Plodkowski, A. J., Arbour, K. C., Chaft, J. E., et al. (2018) · Annals of Oncology

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 908

EGFR -Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes

Marcoux, N., Gettinger, S. N., O’Kane, G., Arbour, K. C., Neal, J. W., Husain, H., Evans, T. L., Brahmer, J. R., Muzikansky, A., Bonomi, P. D., et al. (2019) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 500

Diverse alterations associated with resistance to KRAS(G12C) inhibition

Zhao, Y., Murciano-Goroff, Y. R., Xue, J. Y., Ang, A., Lucas, J., Mai, T. T., Da Cruz Paula, A. F., Saiki, A. Y., Mohn, D., Achanta, P., et al. (2021) · Nature

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 479

Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS -Mutant Non–Small Cell Lung Cancer

Arbour, K. C., Jordan, E., Kim, H. R., Dienstag, J., Yu, H. A., Sanchez-Vega, F., Lito, P., Berger, M., Solit, D. B., Hellmann, M., et al. (2018) · Clinical Cancer Research

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 466

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib

Schoenfeld, A. J., Arbour, K. C., Rizvi, H., Iqbal, A. N., Gadgeel, S. M., Girshman, J., Kris, M. G., Riely, G. J., Yu, H. A., & Hellmann, M. D. (2019) · Annals of Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 406

Diminished efficacy of programmed death-(ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status

Ricciuti, B., Arbour, K. C., Lin, J. J., Vajdi, A., Vokes, N., Hong, L., Zhang, J., Tolstorukov, M. Y., Li, Y. Y., Spurr, L. F., et al. (2022) · Journal of Thoracic Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 394

Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers

Jiang, J., Jiang, L., Maldonato, B. J., Wang, Y., Holderfield, M., Aronchik, I., Winters, I. P., Salman, Z., Blaj, C., Menard, M., et al. (2024) · Cancer Discovery

Protein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases

Cited by 343

Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation

Sacher, A., LoRusso, P., Patel, M. R., Miller, W. H., Garralda, E., Forster, M. D., Santoro, A., Falcon, A., Kim, T. W., Paz-Ares, L., et al. (2023) · New England Journal of Medicine

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 328

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

Skoulidis, F., Araujo, H. A., Do, M. T., Qian, Y., Sun, X., Galan-Cobo, A., Le, J. T., Montesion, M., Palmer, R., Jahchan, N., et al. (2024) · Nature

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 194

Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

Desai, J., Alonso, G., Kim, S. H., Cervantes, A., Karasic, T., Medina, L., Shacham-Shmueli, E., Cosman, R., Falcon, A., Gort, E., et al. (2024) · Nature Medicine

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 144

Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer

Ricciuti, B., Alessi, J. V., Elkrief, A., Wang, X., Cortellini, A., Li, Y. Y., Vaz, V. R., Gupta, H., Pecci, F., Barrichello, A., et al. (2022) · Annals of Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 112

Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer

Skoulidis, F., Arbour, K. C., Hellmann, M. D., Patil, P. D., Marmarelis, M. E., Awad, M. M., Murray, J. C., Hellyer, J., Gainor, J. F., Dimou, A., et al. (2019) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers

Cited by 102

Abstract PR014: Preliminary safety and anti-tumor activity of RMC-6291, a first-in-class, tri-complex KRASG12C (ON) inhibitor, in patients with or without prior KRASG12C (OFF) inhibitor treatment

Jänne, P. A., Bigot, F., Papadopoulos, K., Eberst, L., Sommerhalder, D., Lebellec, L., Voon, P. J., Pellini, B., Kalinka, E., Arbour, K., et al. (2023) · Molecular Cancer Therapeutics

Protein Kinase Regulation and GTPase SignalingLung Cancer Treatments and Mutations

Cited by 63

Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers

Drilon, A., Schoenfeld, A. J., Arbour, K. C., Litvak, A., Ni, A., Montecalvo, J., Yu, H. A., Panora, E., Ahn, L., Kennedy, M., et al. (2019) · Molecular Case Studies

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 31

Abstract LB002: Mechanisms of acquired resistance to KRAS G12C inhibition in cancer

Awad, M., Liu, S., Arbour, K., Zhu, V., Johnson, M., Heist, R., Patil, T., Riely, G., Jacobson, J., Dilly, J., et al. (2021) · Cancer Research

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 12

Computational biomarker predicts lung ICI response via deep learning-driven hierarchical spatial modelling from H&E

Xie, C., Vanderbilt, C., Feng, C., Ho, D., Campanella, G., Egger, J., Plodkowski, A., Girshman, J., Sawan, P., Arbour, K., et al. (2022) · Research Square

AI in cancer detectionCancer Immunotherapy and Biomarkers

Cited by 8

RRAS and RRAS2 mutations are recurrent oncogenic drivers in lung cancer and are sensitive to the pan-RAS inhibitor RMC-6236

Pfeil, A. J., Zhang, T., Cheng, R., Mattar, M. S., Gomez Marti, J. L., Gili, L., Lai, R., Khodos, I., Master, R. P., Dix, J.-M., et al. (2025) · Clinical Cancer Research

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 3